CHIMERIC MCP AND DAF PROTEINS WITH CELL SURFACE LOCALIZING DOMAIN

Abstract: Chimeric proteins containing sequences from MCP and DAF and further containing peptide sequences capable of binding glycosaminoglycans. Nucleotide sequences encoding the chimeric proteins, expression vectors containing the nucleotide sequences, as well as transformed host cells capable of producing the chimeric proteins are claimed.

Description: CHIMERIC MCP AND DAF PROTEINS WITH CELL SURFACE LOCALIZING DOMAIN BACKGROUND OF THE INVENTION Field of the Invention The invention relates to fusion proteins containing sequences from the complement inhibitors membrane co-factor protein (hereinafter 'MCP') and decay accelerating factor (hereinafter 'DAF') wherein the fusion proteins also contain at least one cell surface localizing domain. Description of the Prior Art Complement is an important defense mechanism for warding off infectious agents. Complement works by targeting microorganisms and other antigens to complement-receptor-bearing cells, recruiting phagocytic cells to the area where complement activation is taking place and the destruction of target membrane. Complement is a cascade of over 30 proteins and is turned on during inflammation. Indeed, the complement components C3a, C4a and C5a trigger the release of inflammatory mediators from mast cells, induce smooth muscle contraction, increase vessel permeability and recruit neutrophils. In some cases, inflammation and the accompanying activation of complement results in damage to host tissues. Sepsis, Adult Respiratory Distress Syndrome (hereinafter ΑRDS 1 ), reperfusion injury and burns are among the clinically significant conditions in which amplification of complement activation results in tissue damage. Complement is regulated in part by six proteins with closely related primary sequence structure including Membrane Cofactor Protein (hereinafter 'MCP') and Decay Accelerating Factor (hereinafter 'DAF'). The genes encoding MCP and DAF, as well as four other complement regulating proteins have been localized to the long arm of human chromosome 1, band lq32. All six of these proteins have a common structural motif with an approximately 60-amino acid consensus unit or short consensus repeat (hereinafter 'SCR') and are present in four contiguous copies in MCP and DAF. Although not completely identical in sequence, the SCRs have invariant cysteines at four positions and up to 18 highly conserved positions throughout the rest of the sequence. MCP (also known as 'CD46') is present on the cell surface of a number of cell types including peripheral blood cells (excluding erythrocytes), cells of epithelial, endothelial and fibroblast lineages, trophoblasts and sperm. MCP has four SCR sequences and serine/threonine enriched region in which heavy O- linked glycosylation occurs. MCP also has a transmembrane and cytoplasmic domain. MCP works by binding to the C3b and C4b present on the cell surface thereby targeting the protein for degradation by factor I, a plasma protease, and thereby destroying any C3 or C4 convertase activity. Thus, MCP is said to have "cofactor activity". B-ecause MCP is localized on the cell surface, it protects only the cells on which it is present and is therefore said to act in an intrinsic manner. The sequence of a cDNA encoding human MCP has been reported by Lublin et al, J. Exp. Med., (1988) 265:181-194. DAF is present on the cell surface of a number of cell types including peripheral blood cells (including erythrocytes), cells of epithelial, endothelial and fibroblast lineages, trophoblasts and sperm. DAF regulates complement function via "decay accelerating activity". That is, DAF binds to C4b/C2a and to C3b/Bb and destabilizes the association of C2a or Bb (the protease component) thus destroying the C3 convertase activity. DAF has also been reported to interfere with the formation of C4b/C2a and C3b/Bb complexes. As with MCP, DAF regulates complement in an intrinsic manner, thus protecting only the cells on which DAF is located. The sequence of cDNA encoding human DAF has been reported by Medof et al, Proc. Nat. Acad. Sci. USA (1987) 84:2007, and by Caras et al, Nature, (1987) 325:545-549. The disclosure of both articles is herein incorporated by reference. Like MCP, DAF has four SCR sequences and a serine/threonine enriched region in which heavy O-linked glycosylation occurs. DAF has a cell surface localizing domain at it carboxy terminal end at which a glycophosphatidylinositol moiety (hereinafter 'GPI') is covalently bound. The GPI links DAF to cell surfaces and even allows for reattachment of DAF to cell surfaces after solubilization of cell membranes with detergent Caras et al report the finding of two mRNAs encoding DAF. One species encodes DAF with the cell surface localizing domain. The second species accounts for 10% of DAF mRNA and appears to encode a secreted species of DAF which is lacking the cell surface localizing domain to which the GPI-anchor is attached. This cell surface localizing domain appears to be important for the optimal function of DAF. Patients with paroxysmal nocturnal hemoglobinuria are known to be deficient in GPI-anchored proteins and this deficiency is known to causally related to susceptibility of their blood cells to lysis by complement Moreover, Moran et al, J. Immunol,. (1992) 149:1736-1743 have shown that recombinant full length DAF and recombinant DAF which is missing the cell surface localizing domain (seDAF) both protect cells against complement but that mDAF was 50 fold more potent than seDAF. However, mDAF must be incorporated into cell surface membranes to have the higher level of activity and it appears that serum lipoproteins interfere with this incorporation. This observation led Moran et al to the conclusion that seDAF will be the preferred molecule for clinical applications. Lublin and Coyne, J. Exp. Med. (1991) 274:35-44 compared the activity of DAF, MCP, and variants of DAF and MCP in which the cell-surface membrane localizing domains of DAF and MCP (the GPI-anchor of DAF and the transmembrane (TM) domain of MCP) had been exchanged. Interestingly, DAF and the DAF/MCP-TM variant showed approximately equal complement inhibiting activity. Likewise, MCP and the MCP/DAF-GPI anchor variant showed approximately equal complement inhibiting activity in vitro. Hybrid complement regulatory proteins containing DAF and MCP in a single polypeptide have been disclosed. See e.g. Iwata et al, J. Immunol., (1994) 252:3436-3444. Iwata et al disclose that MCP-DAF hybrids are more effective than DAF, MCP or DAF and MCP at inhibiting C3 deposition via the alternative pathway. The MCP-DAF hybrid was also more effective than MCP alone at inhibiting C3 deposition via the classical pathway. SUMMARY OF THE INVENTION The present invention provides chimeric proteins in which MCP, DAF and MCP-DAF hybrids are produced with cell surface localizing domains which target the molecules to cell surfaces, thereby increasing the concentration of these molecules on cell surfaces where they can act to inhibit complement- mediated cell lysis. It will be appreciated that such molecules will be useful in prevention and treatment of disease states in which complement plays a role in causing the disease state. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is a DNA sequence containing the coding region of an MCP-DAF hybrid molecule. DETAILED DESCRIPTION OF THE INVENTION The chimeric proteins of the invention comprising MCP-DAF hybrids may be represented by the following formula: The Ri component may comprise MCP or DAF. The R 2 component comprises DAF when Ri comprises MCP and the R 2 component comprises MCP when Ri comprises DAF. The B component may be a peptide of any length, including zero, and may or may not have biological activity including complement ύihibiting activity. The flanking peptide sequences, A and C, are usually 6 or more amino acids in length and have cell surface localization properties. Alternatively, A may be a precursor sequence which is cleaved from the molecule after translation. It will be understood that A or C may be zero amino acids in length, however a peptide sequence having glycosaminoglycan binding ability will always be present in at least the A or the C position. It will be further understood that when peptide sequences are present in the A and the C positions, that A and C may be but need not be the same sequence and may have different glycosaminoglycan binding abilities. As used herein 'MCP' means a protein having the complement inhibiting activity of mature MCP as disclosed in Lublin et al at Figure 1 on page 184. (.See below at Example 5 for assays to determine the complement-inhibiting activity of proteins containing MCP sequence). The disclosure of Lublin et al is herein incorporated by reference. It will be recognized by those skilled in the art that the entire amino acid sequence disclosed by Lublin et al will not be required for complement inhibiting activity. That is, portions of the mature MCP sequence can be deleted and yet the protein retains complement inhibiting activity. Examples of portions of MCP that could be deleted include the cytoplasmic tail and the transmembrane domain. Naturally occurring allelic variants containing amino acid substitutions retaining the complement inhibiting activity are included within the definition as are artificially produced muteins of MCP (that is, MCP with 1 to 5 amino acid substitutions). Naturally occurring and artificially produced variants of MCP, such as those described in Liszewski et al, Ann. Rev. Immunol., (1991) 9:431-455 and in WO 91/18097, are also included within the definition of MCP. The disclosures Liszewski et al and of WO 91/18097 are herein incorporated by reference. One portion of MCP useful in the molecules of the invention is: CysGluGluProProThrPheGluAlaMetGluLeuIleGlyLysProLysProTyrTy rGluIleGlyGluArgValAspTyrLysCysLysLysGlyTyrPheTyrlleProProL euAlaThrHisThrlleCysAspArgAsnHisThrTrpLeuProValSerAspAspAla CysTyrArgGluThrCysProTyrlleArgAspProLeuAsnGlyGlnAlaValProAl •aAsnGlyThrTyrGluPheGlyTyrGlnMetHisPhelleCysAsnGluGlyTyrTyrL eulleGlyGluGluIleLeuTyrCysGluLeuLysGlySerValAlalleTrpSerGly LysProProIleCysGluLysValLeuCysThrProProProLysIleLysAsnGlyLy sHisThrPheSerGluValGluValPheGluTyrLeuAspAlaValThrTyrSerCysA spProAlaProGlyProAspProPheSerLeuIleGlyGluSerThrlleTyrCysGly AspAsnSerValTrpSerArgAlaAlaProGluCysLysValValLysCysArgPhePr oValValGluAsnGlyLysGlnlleSerGlyPheGlyLysLysPheTyrTyrLysAlaT hrValMetPheGluCysAspLysGlyPheTyrLeuAspGlySerAspThrlleValCys AspSerAsnSerThrTrpAspProProValProLysCysLeuLysValSerThr (SEQIDNO:1) DAF as used herein means a protein having the complement inhibiting activity of mature DAF as disclosed in Caras et al at Figure la on page 546. The disclosure of Caras et al is herein incorporated by reference. It will be recognized by those skilled in the art that the entire amino acid sequence disclosed by Caras et al will not be required for complement inhibiting activity. That is, portions of the mature DAF sequence can be deleted and yet the protein retains complement inhibiting activity. Examples of portions of DAF that could be deleted include the GPI-anchor domain. Naturally occurring allelic variants containing amino acid substitutions retaining the complement inhibiting activity are included within the definition as are artificially produced muteins of DAF (that is, DAF with 1 to 5 amino acid substitutions). Examples of muteins may be found in EP 0244267. Naturally occurring variants, such as the secreted variant described by Caras et al, are included within the definition of DAF. One portion of DAF useful in the molecules of the invention is: AspCysGlyLeuProProAspValProAsnAlaGlnProAlaLeuGluGlyArgThrSe rPheProGluAspThrVallleThrTyrLysCysGluGluSerPheValLysIleProG lyGluLysAspSerVallleCysLeuLysGlySerGlnTrpSerAspIleGluGluPhe CysAsnArgSerCysGluValProThrArgLeuAsnSerAlaSerLeuLysGlnProTy rIleThrGlnAsnTyrPheProValGlyT rValValGluTyrGluCysArgProGlyT yrArgArgGluProSerLeuSerProLysLeuThrCysLeuGlnAsnLeuLysTrpSer ThrAlaValGluPheCysLysLysLysSerCysProAsnProGlyGluIleArgAsnGl yGlnlleAspValProGlyGlylleLeuPheGlyAlaThrlleSerPheSerCysAsnT hrGlyTyrLysLeuPheGlySerThrSerSerPheCysLeuIleSerGlySerSerVal GlnTrpSerAspProLeuProGluCysArgGluIleTyrCysProAlaProProGlnll ΘAspAsnGlyllelleGlnGlyGluArgAspHisTyrGlyTyrArgGlnSerValThrT yrAlaCysAsnLysGlyPheThrMetlleGlyGluHisSerlleTyrCysThrValAsn AsnAspGluGlyGluTrpSerGlyProProProGluCysArgGlyLysSerLeuThrSe rLysValProProThrValGlnLysProThrThrValAsnValProThrThrGluValS erProThrSerGlnLysThrThrThrLysThrThrThrProAsnAlaGlnAlaThrArg SerThrProValSerArgThrThrLysHisPheHisGluThrThrProAsnLysGlySe rGlyThrThrSerGlyThrThrArg (SEQIDNO:2) MCP-DAFhybrids asusedhereinmeanspolypeptidescontaύiingMCP andDAFasthoseterms aredefinedinthissection. Forinstance, MCP-DAF hybridsmaycontaintheentiresequenceofbothmolecules andmaycontainjust theSCRregionsfromeachMCPandDAF. AnexampleofanMCP-DAFhybrid isthemoleculedisclosedbyIwata et al, suprahavingthefirst250aminoacidsof MCPcovalentlylinkedtoDAF. SequencesseparatingtheMCPandDAF portionsmaybeintroducedaswell. TheMCP-DAFhybridmoleculemayalso havethefollowingamino-acid sequence: CysGluGluProProThrPheGluAlaMetGluLeuIleGlyLysProLysProTyrTy rGluIleGlyGluArgValAspTyrLysCysLysLysGlyTyrPheTyrlleProProL euAlaThrHisThrlleCysAspArgAsnHisThrTrpLeuProValSerAspAspAla CysTyrArgGluThrCysProTyrlleArgAspProLeuAsnGlyGlnAlaValProAl aAsnGlyThrTyrGluPheGlyTyrGlnMetHisPheIleCysAsnGluGlyTyrTyrL eulleGlyGluGluIleLeuTyrCysGluLeuLysGlySerValAlalleTrpSerGly LysProProIleCysGluLysValLeuCysThrProProProLysIleLysAsnGlyLy sHisThrPheSerGluValGluValPheGluTyrLeuAspAlaValThrTyrSerCysA spProAlaProGlyProAspProPheSerLeuIleGlyGluSerThrlleTyrCysGly AspAsnSerValTrpSerArgAlaAlaProGluCysLysValValLysCysArgPhePr oValValGluAsnGlyLysGlnlleSerGlyPheGlyLysLysPheTyrTyrLysAlaT hrValMetPheGluCysAspLysGlyPheTyrLeuAspGlySerAspThrlleValCys AspSerAsnSerThrTrpAspProProValProLysCysLeuLysValSerThrAspCy sGlyLeuProProAspValProAsnAlaGlnProAlaLeuGluGlyArgThrSerPheP roGluAspThrVallleThrTyrLysCysGluGluSerPheValLysIleProGlyGlu LysAspSerVallleCysLeuLysGlySerGlnTrpSerAspIleGluGluPheCysAs nArgSerCysGluValProThrArgLeuAsnSerAlaSerLeuLysGlnProTyrlleT hrGlnAsnTyrPheProValGlyThrValValGluTyrGluCysArgProGlyTyrArg ArgGluProSerLeuSerProLysLeuThrCysLeuGlnAsnLeuLysTrpSerThrAl aValGluPheCysLysLysLysSerCysProAsnProGlyGluIleArgAsnGlyGlnl leAspValProGlyGlylleLeuPheGlyAlaThrlleSerPheSerCysAsnThrGly TyrLysLeuPheGlySerThrSerSerPheCysLeuIleSerGlySerSerValGlnTr pSerAspProLeuProGluCysArgGluIleTyrCysProAlaProProGlnlleAspA snGlyllelleGlnGlyGluArgAspHisTyrGlyTyrArgGlnSerValThrTyrAla CysAsnLysGlyPheThrMetlleGlyGluHisSerlleTyrCysThrValAsnAsnAs pGluGlyGluTrpSerGlyProProProGluCysArgGlyLysSerLeuThrSerLysV alProProThrValGlnLysProThrThrValAsnValProThrThrGluValSerPro ThrSerGlnLysThrThrThrLysThrThrThrProAsnAlaGlnAlaThrArgSerTh rProValSerArgThrThrLysHisPheHisGluThrThrProAsnLysGlySerGlyT hrThrSerGlyThrThrArg (SEQIDNO:3). The chimeric proteins of the invention include proteins with sequences which inhibit complement function and s-equences which bind to glycosaminoglycans present on cell surfaces, particularly heparin. The sequences which inhibit complement function are MCP, DAF and MCP-DAF hybrids. These peptide sequences preferably have glycosaminoglycan binding ability and, most preferably, bind heparin. Consensus sequences capable of binding heparin have been identified by Cardin and Weintraub, Arteriosclerosis, (1989) 9:21-32 and by Sobel et al. (1992) J. Biol. Chem. 267:8857-8862. The consensus sequence can be represented as follows: XBBXXBBBXXBBX where X represents hydropathic amino acids and B represents the basic amino acids lysine and arginine. One example of a peptide according to the consensus is Ala-Lys-Arg-Gly-Leu-Arg-Arg-Arg-Leu-Gly-Arg-Lys-Ala (SEQ ID NO: 4). A second consensus sequence can be represented by: XBBXBX where X represents hydropathic amino acids and B represents the basic amino acids lysine and arginine. An example of this shorter sequence is Ala-Arg-Arg- Gly-Lys-Leu (SEQ ID NO: 5). Any sequence matching the two consensus sequences described may be used in the A or the C position or both to target the MCP-DAF hybrid to cell surfaces. Two sequences derived from fibronectin can also be used as glycosaminoglycan binding sequences. The first Trp-Gln-Pro-Pro-Arg-Ala- Arg-He (SEQ ID NO: 6) was identified by Woods et al., Molec. Biol. Cell (1993) 4:605-613. The second, Leu-Ile-Gly-Arg-Lys-Lys (SEQ ID NO: 7) was described by Drake et al, J.Biol.Chem., (1993) 265:15859-15867. Peptide sequences having glycosaminoglycan binding ability may be derived from proteins having heparin binding activity including, but not limited to, the following: protease nexin-1, protease nexin-2, antithrombin UJ, protein C inhibitor, platelet factor 4, heparin cofactor U, ghilanten-related inhibitors, bovine pancreatic trypsin inhibitor, tissue factor pathway inhibitor (hereinafter 'TFPI') (also known as LACL TFI and EPI) or TFPI-2. In the case of antithrombin UJ, the appropriate portion may be Ala Lys Leu Asn Cys Arg Leu Tyr Arg Lys Ala Asn Lys Ser Ser Lys Leu. (SEQ ID NO: 8). The appropriate portion of antithrombin HI may also be Thr .Ser Asp Gin He His Phe Phe Phe Ala Lys Leu Asn Cys Arg. (SEQ ID NO: 9). In the case of protein C inhibitor, the appropriate portion may be Ser Glu Lys Thr Leu Arg Lys Trp Leu Lys Met Phe Lys Lys Arg Glu Leu Glu Glu Tyr (SEQ ID NO: 10). The appropriate portion of protein C inhibitor may also be His Arg His His Pro Arg Glu Met Lys Lys Arg Val Glu Asp Leu (SEQ ID NO: 11). In the case of heparin cofactor LL the appropriate portion may be Phe Arg Lys Leu Thr His Arg Leu Phe Arg Arg Asn Phe Gly Tyr Thr Leu Arg (SEQ ID NO: 12). In the case of platelet factor 4, the appropriate portion may be Leu Tyr Lys Lys lie Leu Lys Lys Leu Leu Glu Ala (SEQ ID NO: 13). In the case of ghilanten-related inhibitors, the appropriate portion may be Asn Gly Leu Lys Arg Asp Lys Leu Gly Cys Glu Tyr Cys Glu Cys Arg Pro Lys Arg Lys Leu He Pro Arg Leu Ser (SEQ ID NO: 14). In the case of TFPL the appropriate portion may be Lys Thr Lys Arg Lys Arg Lys Lys Gin Arg Val Lys He Ala Tyr Glu Glu lie Phe Val Lys Asn Met (SEQ ID NO: 15). In the case of TFPI-2, the appropriate portion may be Lys Lys Lys Lys Lys Met Pro Lys Leu Arg Phe Ala Ser Arg lie Arg Lys De Arg Lys Lys Gin Phe (SEQ ID NO: 16). Those skilled in the art will appreciate that various deletions, substitutions and insertions may be made to the above-listed sequences without substantially interfering with the ability of the sequence to bind to heparin. Such modifications to the above-listed sequences should be understood to fall within the scope of the invention. Production of Chimeric Proteins of the Invention One skilled in the art of DNA cloning and in possession of the DNA encoding MCP, DAF, and a cell surface localizing domain is able to prepare suitable DNA molecules for production of such chimeric proteins using known cloning procedures (e.g. restriction enzyme digestion of MCP, DAF, or cell surface localizing domain encoding DNA, exonuclease digestion, ligation, and other appropriate procedures) outlined in any of the following: Sambrook, et al, MOLECULAR CLONING: A LABORATORY MANUAL 2nd ed. (Cold Spring Harbor Laboratory Press, 1989); DNA CLONING, Vol. I and IL D.N. Glover ed. (IRL Press, 1985); OLIGONUCLEOTIDE SYNTHESIS, MJ. Gait ed. (IRL Press, 1984); NUCLEIC ACID HYBRIDIZATION, B.D. Hames & S.J. Higgins eds. (IRL Press, 1984); TRANSCRIPTION AND TRANSLATION, B.D. Hames & S.J. Higgins eds., (IRL Press, 1984); ANIMAL CELL CULTURE, R.L Freshney ed. (IRL Press, 1986); IMMOBILIZED CELLS AND ENZYMES, K. Mosbach (IRL Press, 1986); B. Perbal, A PRACTICAL GUIDE TO MOLECULAR CLONING, Wiley (1984); the series, METHODS IN ENZYMOLOGY, Academic Press, Inc.; GENE TRANSFER VECTORS FOR MAMMALIAN CELLS, J.H. Miller and M.P. Calos eds. (Cold Spring Harbor Laboratory, 1987); METHODS IN ENZYMOLOGY, Vol. 154 and 155, Wu and Grossman, eds., and Wu, ed., respectively (Academic Press, 1987), IMMUNOCHEMICAL METHODS IN CELL AND MOLECULAR BIOLOGY, RJ. Mayer and J.H. Walker, eds. (Academic Press London, Harcourt Brace U.S., 1987), PROTEIN PURIFICATION: PRINCIPLES AND PRACTICE, 2nd ed. (Springer-Verlag, N.Y. (1987), and HANDBOOK OF EXPERIMENTAL IMMUNOLOGY, Vol. I-IV, D.M. Weir et al, (Blackwell Scientific Publications, 1986); Kitts et al, Biotechniques, (1993), 24:810-817; Munemitsu et al, Mol. Cell. BioL, (1990) 20:5977-5982. Alternatively, the entire sequence or portions of nucleic acid sequences encoding proteins described above may be prepared by synthetic methods (e.g. using DNA synthesis machines). Finally, a preferred method of preparing nucleic acid molecules encoding the described chimeric proteins is by use of PCR techniques, especially overlapping PCR, as described in PCR PROTOCOLS: A GUIDE TO METHODS AND APPLICATIONS, Innis, Gelfand, Sninsky, and White (eds.) (Academic Press, 1990). The proteins described above may be prepared using any suitable expression system including, without limitation, the following expression systems: mammalian tissue culture, insect cell culture, bacterial cell culture and yeast cell culture. It will be understood that the proteins of the invention may be within the cells as precursor molecules which may be cleaved within the cells to produce the desired protein. Alternatively, the precursor proteins may be recovered from the cells and further processed to recover the desired protein. Mammalian expression systems are known in the art Sambrook et al "Expression of Cloned Genes in Mammalian Cells." In MOLECULAR CLONLNG: A LABORATORY MANUAL 2nd ed. (Cold Spring Harbor Laboratory Press, 1989). Mammalian cell lines available as hosts for expression are known in the art and include many immortalized cell lines available from the American Type Culture Collection (ATC . The proteins of the invention may also be produced in insect cells using a vector containing baculovirus sequences. Materials and methods for baciilovirus/insect cell expression systems are commercially available in kit form from, inter alia, Invitrogen, San Diego CA ("MaxBac" kit). These techniques are generally known to those skilled in the art and fully described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987) (hereinafter "Summers and Smith"). Currently, the most commonly used transfer vector for introducing foreign genes into AcNPV is pAc373. Many other vectors, known to those of skill in the art, have also been designed. These include, for example, pVL985 (which alters the polyhedrin start codon from ATG to ATT, and which introduces a BamHI cloning site 32 base pairs downstream from the ATT; see Luckow and Summers, Virology (1989) 27:31. Methods for introducing heterologous DNA into the desired site in the baculovirus virus are known in the art (-See Summers and Smith, supra; Ju et al (1987); Smith et al, Mol. Cell. Biol, (1983) 3:2156; and Luckow and Summers (1989), supra). For example, the insertion can be into a gene such as the polyhedrin gene, by homologous double crossover recombination; insertion can also be into a restriction enzyme site engineered into the desired baculovirus gene. Miller et al, Bioessays (1989) 4:91. The DNA sequence, when cloned in place of the polyhedrin gene in the expression vector, is flanked both 5' and 3' by polyhedrin-specific sequences and is positioned downstream of the polyhedrin promoter. Recombinant baculovirus expression vectors have been developed for infection into several insect cells. For example, recombinant baculoviruses have been developed for, inter alia: Aedes aegypti, Bo byx mori, Drosophila melanogaster, Spodopterafrugiperda, and Trichoplusia ni (PCT Pub. No. WO 89/046699; CarboneU et al, }. Virol. (1985) 56:153; Wright, Nature (1986) 322 :718; Smith et al, Mol. Cell. Biol, (1983) 3:2156; and see generally, Fraser, et al Cell. Deo. Biol, (1989) 25:225. Cells and cell culture media are commercially available for both direct and fusion expression of heterologous polypeptides in a baculovirus/expression system; cell culture technology is generally known to those skilled in the art See, e.g., Summers and Smith , supra. The modified insect cells may then be grown in an appropriate nutrient medium, which allows for stable maintenance of the plasmid(s) present in the modified insect host One such nutrient medium is described in EP 380495. Numerous bacterial expression techniques are known in the art Sambrook et al "Expression of cloned genes in Escheridiia coli." In MOLECULAR CLONING: A LABORATORY MANUAL 2nd ed. (Cold Spring Harbor Laboratory Press, 1989). Expression and transformation vectors, either extra-chromosomal replicons or integrating vectors, have been developed for transformation into many bacteria. For example, expression vectors have been developed for, inter alia, the following bacteria: Bacillus subtϊlis (Palva et al , Proc. Natl. Acad. Sci. USA, (1982) 79:5582; EP 036259 and 063 953; PCT WO 84/04541), E. coli (Shimatake et al., Nature, (1981) 292:128; Amann et al , Gene (1985) 40:183; Shadier et al , ]. Mol. Biol, (1986) 1S9:113; EP Publ. Nos. 036776, 136 829 and 136907), Streptococcus cremoris (Powell et al., Appl. Environ. Microbiol., (1988) 54:655); Streptococcus lividans (Powell et al., Appl. Environ. Microbiol., (1988) 54:655), Streptomyces lividans (U.S. Patent No. 4,745,056). The DNA encoding the protein of the present invention may be joined to a signal peptide for export or secretion of the mature protein to the periplasmic space of bacteria, using techniques that are conventional in the art Moreover, transcription and translation can further be optimized in a bacterial expression system by varying the spacing between the DNA to be expressed and the sequences encoding the promoter and ribosome binding site. Yeast expression systems are also known in the art Fusion proteins provide one means for expression of the proteins of the invention in yeast systems. Usually, a DNA sequence encoding the N-terminal portion of an endogenous yeast protein, or other stable protein, is fused to the 5' end of a heterologous coding sequence. Upon expression, this construct will provide a fusion of the two amino acid sequences. The DNA sequence at the junction of the two amino acid sequences may or may not encode a cleavable site. See e.g., EP 196 056. One such fusion protein is a ubiquitin fusion protein. Such a fusion protein is made with the ubiquitin region that may retain a site for a processing enzyme, which allows a ubiquitin-specific processing protease to cleave the ubiquitin from the foreign protein. Through this method, therefore, foreign protein with an authentic amino terminus can be isolated from within the yeast cell. Production of ubiquitin fusion proteins is described in co-pending U.S. Patent Application Serial Nos. 07/806,813 and 07/957,627. This method is reviewed in Barr et al, in RECOMBINANT SYSTEMS IN PROTEIN EXPRESSION (Elsevier Science Publishers B.V., 1991), pp. 37-46. Alternatively, foreign proteins can be secreted from the cell into the growth media by creating chimeric DNA molecules that encode a fusion protein comprised of a leader sequence fragment that provide for secretion in yeast of the foreign protein. There may be processing sites encoded between the leader fragment and the foreign gene that can be cleaved either in vivo or in vitro. The leader sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell. DNA encoding suitable signal sequences can be derived from genes for secreted yeast proteins, such as the yeast invertase gene (EP 012873; TPO 62,096,086), the α-factor gene (U.S. Patent Nos. 4,588,684 and 4,870,008; EP 116,201) and truncated versions of the α-factor gene as described in EP 324 274 and co-pending U.S. Patent Application Serial No. 07/864,206. Alternatively, leaders of non-yeast origin, such as an interferon leader, exist that also provide for secretion in yeast (EP 060 057). The α-factor gene may be used in nucleic acid constructs designed for secretion of the proteins of the invention. Another useful class of secretion leaders are those that employ a fragment of the yeast α-factor gene, which contains both a "pre" signal sequence, and a "pro" region. The types of α-factor fragments that can be employed include the full-length pre-pro α factor leader (about 83 amino acid residues) as well as truncated α-factor leaders (usually about 25 to about 50 amino acid residues) (U.S. Patent Nos. 4,546,083 and 4,870,008; EP 324 274). Additional leaders employing an α-factor leader fragment that provides for secretion include hybrid α-factor leaders made with a presequence of a first yeast, but a pro- region from a second yeast α-factor. (See e.g., PCT WO 89/02463.) Expression vectors encoding the proteins of the invention are often maintained in a replicon, such as an extrachromosomal element (e.g., plasmid) capable of stable maintenance in a host, such as yeast or bacteria. The replicon may have two replication systems, thus allowing it to be maintained, for example, in yeast for expression and in a procaryotic host for cloning and amplification. Examples of such yeast-bacteria shuttle vectors include YEp24 (Botstein et al, Gene, (1979) 5:17-24), pCl/1 (Brake et al, Proc. Natl. Acad. Sci USA, (1984) 52:4642-4646), and YRpl7 (Stinchcomb et al, ]. Mol. Biol, (1982) 155:157). In addition, a replicon may be either a high or low copy number plasmid. A high copy number plasmid will generally have a copy number ranging from about 5 to about 200, and usually about 10 to about 150. A host containing a high copy number plasmid will may have at least about 10, and may have at least about 20. Either a high or low copy number vector may be selected, depending upon the effect of the vector and the foreign protein on the host See e.g., Brake et al, supra. For production of the proteins of the invention in a yeast cell wherein the protein is retained within the yeast cell, a plasmid such as pAB24 may be used. Sabin et al, Bio/Technology, (1989) 7:705-709. ρAB24 contains a GAP/ ADH hybrid promoter, containing portions of an ADH promoter capable of directing high levels of expression of the sequences under its control but which also contains GAP regulatory sequences, allowing expression of the same sequence a desired point in the growth of a culture. Alternatively, the expression constructs can be integrated into the host genome with an integrating vector. Integrating vectors usually contain at least one sequence homologous to a host chromosome that allows the vector to integrate, and may contain two homologous sequences flanking the expression construct Integrations appear to result from recombinations between homologous DNA in the vector and the host chromosome. Orr-Weaver et al, Meth. EnzymoL, (1983) 102:228-245. An integrating vector may be directed to a specific locus in yeast by selecting the appropriate homologous sequence for inclusion in the vector. See Orr-Weaver et al, supra. One or more expression construct may integrate, possibly affecting levels of recombinant protein produced. Rine et al, Proc. Natl. Acad. Sci. USA, (1983) 50:6750. The chromosomal sequences included in the vector can occur either as a single segment in the vector, which results in the integration of the entire vector, or two segments homologous to adjacent segments in the chromosome and flanking the expression construct in the vector, which can result in the stable integration of only the expression construct Usually, extrachromosomal and integrating expression constructs may contain selectable markers to allow for the selection of yeast strains that have been transformed. Selectable markers may include biosynthetic genes that can be expressed in the yeast host, such as APE2, HIS4, LEU2, TRP1, and ALG7, and the G418 resistance gene, which confer resistance in yeast cells to tunicamycin and G418, respectively. In addition, a suitable selectable marker may also provide yeast with the ability to grow in the presence of toxic compounds, such as metal. For example, the presence of CUP1 allows yeast to grow in the presence of copper ions (Butt et al, Microbiol. Rev. (1987) 51:351). Alternatively, some of the above described components can be put together into transformation vectors. Transformation vectors are usually comprised of a selectable marker that is either maintained in a replicon or developed into an integrating vector, as described above. Expression and transformation vectors, either extrachromosomal rephcons or integrating vectors, have been developed for transformation into many yeasts. For example, expression vectors have been developed for, inter alia, the following yeasts: Candida albicans (Kurtz, et al, Mol. Cell. Biol., (1986) 6:142), Candida maltosa (Kunze, et al, J. Basic Microbiol., (1985) 25:141), Hansenula polymorpha (Gleeson, et al, J. Gen. Microbiol., (1986) 232:3459; Roggenkamp et al, Mol. Gen. Genet, (1986) 202:302), Kluyveromyces fragilis (Das, et al, J. Bacteriol, (1984) 255:1165), Kluyveromyces lactis (De Louvencourt et al, }. Bacteriol, (1983) 154:737; Van den Berg et d, Bio/Technology, (1990) 5:135), Pichia guillerimondii (Kunze et al, J. Basic Microbiol, (1985) 25:141), Pichia pastoris (Cregg, et al, Mol. Cell Biol, (1985) 5:3376; U.S. Patent Nos. 4,837,148 and 4,929,555), Saccharomyces cerevisiae (Hinnen et al, Proc. Natl Acad. Sci. USA, (1978) 75:1929; Ito et al, J. Bacteriol, (1983) 153:163), Schizosaccharomyces pombe (Beach and Nurse, Nature, (1981) 300:706), and Yarrσwia lipolytica (Davidow, et d, Curr. Genet. (1985) 10:380471 and Gaillardin et al, Curr. Genet., (1985) 20:49). Transformation procedures that may be used herein to transform yeast cells include electroporation, as described in "Guide to Yeast Genetics and Molecular Biology," Vol 194 METHODS IN ENZYMOLOGY, C. Guthrie and G.R. Fink, (Academic Press 1991). Other procedures include the transformation of spheroplasts or the transformation of alkali cation-treated intact cells. Such procedures are described in, for example, Kurtz et al, Mol. Cell Biol, (1986) 6:142; Kunze et al, J. Basic Microbiol, (1985) 25:141, for Candida; Gleeson et d, J. Gen. Microbiol, (1986) 132:3459; Roggenkamp et al., Mol. Gen. Genet., (1986) 202:302, for Hansenula; Das et d, J. Bacteriol. (1984) 255:1165; De Louvencourt et al, J. Bacteriol, (1983) 254:1165; Van den Berg et al, Bio Technology, (1990) 5:135 for Kluyveromyces; Cregg et al, Mol. Cell. Biol. 5:3376 (1985); Kunze et al, J. Basic Microbiol, (1985) 25:141; U.S. Patent Nos. 4,837,148 and 4,929,555, for Pichia; Hinnen et al, Proc. Natl Acad. Sci. USA, (1978) 75:1929; Ito et al, J. Bacteriol, (1983) 253:163, for Saccharomyces; Beach and Nurse, Nature, (1981) 300:706, for Schizosaccharomyces; Davidow et al, Curr. Genet., (1985) 10:39; Gaillardin et al, Curr. Genet, (1985) 10:49, for Yarrσvoia. The present invention will now be illustrated by reference to the following examples which set forth particularly advantageous embodiments. However, it should be noted that these embodiments are illustrative and are not to be construed as restricting the invention in any way. EXAMPLES Example 1 A chimeric protein according to the invention is constructed comprising the protein (SEQ ID NO: 3), an MCP-DAF hybrid molecule with the following amino acid sequence attached to the carboxy-terminal end of the MCP-DAF hybrid molecule: Ala-Lys-Arg-Gly-Leu-Arg-Arg-Arg-Leu-Gly-Arg-Lys-Ala (SEQ ID NO: 4). The chimeric protein is constructed using overlapping PCR. The DNA used as the PCR template is (SEQ ID NO: 17) which encodes the MCP- DAF hybrid (SEQ ID NO: 3) along with the MCP signal peptide. The following primer will be used as the 3' end primer to introduce (SEQ ID NO: 4) to the carboxy-terminal end of the MCP-DAF hybrid molecule: CAGAGAATTCTCAAGCTTTTCTACCrAGTCrrC T'C lAGACCTCTT TTAGCTCGGGTAGTACCTGAAGTGGT (SEQ ID NO: 18). The 5' end primer will be: CAGAGGTACCATGGAGCCTCCCGGCCGCCGC (SEQ ID NO: 19). The 5' end primer has a Kpnl and the 3' end primer has an EcoRI site to direct the cloning of the resulting DNA in predigested pAcC13, a plasmid containing baculovirus sequences allowing expression of the DNA in insect cells as described above. A pAcC13 vector containing a PR-3 sequence and useable in the present example has been deposited with the A.T.C.C. as described below. Those skilled in the art will appreciate that the insert present in the deposited plasmid can be removed by methods known in the art Alternatively, a shorter heparin binding sequence, Ala-Arg-Arg-Gly-Lys- Leu (SEQ ID NO: 5), can be added to the carboxy-terminal end of the MCP-DAF hybrid (SEQ ID NO: 3). In this case the primer will be: CAGAGAATTCΓCATAGTΓTACCTCTTCTAGCTCGGGTAGTACCTGA AGTGGT (SEQ ID NO: 20). As before, the 3' end primer has an EcoRI site to direct the cloning of the resulting DNA into pAcC13. Example 2 The heparin binding tail of TFPI can also be used in construction of the chimeric proteins of the invention. In this case, the heparin binding tail Lys- Thr-Lys-Arg-Lys-Arg-Lys-Lys-Gln-Arg-Val-Lys-Ile-Ala-Tyr-Glu-Glu-Ile-Phe- Val-Lys-Asn-Met (SEQ ID NO: 15) is attached to the carboxy-terminal end of the MCP-DAF hybrid (SEQ ID NO: 3). As in Example 1, the DNA encoding the MCP-DAF hybrid along with the MCP signal peptide (SEQ ID NO: 17) is used as the template for overlapping PCR and the 5' end primer is again (SEQ ID NO: 19). The 3' end primer has the nucleotide sequence: CAGAGAATTCTCACATATTTTTAACAAAAATTTCTTCATATGCTAT TTTCACTCrCTGCrrc T Cl T-IlCTTT-IGGTrπTCGGGTAGTACCTGAAG TGGT (SEQ ID NO: 21). The 3' end primer has an EcoRI site allowing directed cloning of the resulting PCR products into pAcC13 for transformation into and expression in insect cells. Alternatively, the PCR is run in two rounds using the following 5' primer: ACTTCAGGTACTACCCGTAAAACCAAAAGA (SEQ ID NO: 22) and the following 3' end primer: TGAAGTCCATGATGGGCATTTTGG'nTTCrnTTCT (SEQ ID NO: 23). To introduce the EcoRI site, a second round of PCR is performed using the same 5' end primer and a 3' end primer having the following sequence: CAGAGAATTCTCACATATTTTTAACAAAAATTTC (SEQ ID NO: 24). Example 3 In this example, the fibronectin derived sequence Trp-Gln-Pro-Pro-Arg- Ala-Arg-He (SEQ ID NO: 6) is attached to the MCP-DAF hybrid (SEQ ID NO: 3). PCR is performed using the 5' end primer (SEQ ID NO: 19) and the 3' primer having the following sequence: CAGAGAATTCTCATATTCTAGCTCTAGGAGGCTGCCATCGGGTAGT ACCTGAAGTGGT (SEQ ID NO: 25). The 5' end primer has a Kpnl and the 3' end primer has an EcoRI site to direct the cloning of the resulting DNA in predigested pAcC13, a plasmid containing baculovirus sequences allowing expression of the DNA in insect cells as described above. Example 4 Another fibronectin sequence is also useful for constructing chimeric proteins according to the invention. The amino acid sequence is Leu-Ile-Gly- Arg-Lys-Lys (SEQ ID NO: 7) and is attached to the carboxy-terminal end of the MCP-DAF hybrid (SEQ ID NO: 3). PCR is performed using the 5' end primer (SEQ ID NO: 19) and the 3' primer having the following sequence: CAGAGAATTCTCAGGTTTTTTTTCTACCTATTAGTCGGGTAGTACCT GAAGTGGT (SEQ ID NO: 26). The 5' end primer has a Kpnl and the 3' end primer has an EcoRI site to dir-ect the cloning of the resulting DNA in predigested pAcC13, a plasmid containing baculovirus sequences allowing expression of the DNA in insect cells as described above. Example 5 Assay for Complement Inhibiting Activity of Chimeric Proteins of the Invention Inhibition of Classical Pathway Activation Human serum is diluted in Gelatin Veronal Buffer (GVB) (Sigma, St Louis, MO Catalog #G-6514) to yield sufficient complement to effect 70% maximum hemolysis. Dilutions may range from 1:10 to 1:120. IgM-sensitized sheep red blood cell (SRBC) suspension (Diamedix CH50 Test Kit #789-001) is transferred to a centrifuge tube and spun at 500 x g for 1 minute (2 to 8 degrees Q. Two ml of the supernatant Hquid is removed and the SRBC are resuspended in the remaining 1 ml. This preparation is then stored in an ice water bath. The foUowing are then added to dupHcate weUs of a V-bottom microtiter plate: Experimentals containing 100 μl SRBC suspension; 50 ul GVB; 50 ul each serum dilution Negative control containing 100 μl SRBC suspension; 100 μl GVB Maximum lysis control containing 100 μl of SRBC suspension which has been spun down as above and resuspended in 200 μl of water The plate is incubated at 37 degrees C for 30 minutes. The plates are then subjected to centrifugation at 500 x g for 1 minute (2 to 8 degrees Q and 100 ul of the resulting supernatant Hquid is drawn off. The absorbance of each sample is then measured at 405 nm. Percent maximum lysis for each serum dilution is then calculated according to the formula: {[O.D.sample-O.D.neg.confrol]/[O.D.maximunι-O.D.neg.control]} x 100. The serum dilution at which approximately 70% maximum lysis occurs is the dilution at which subsequent assays with the molecules of the invention should be performed. This dilution will apply only to the specific lot of human serum tested and must be repeated for each new serum lot Standard solutions containing the molecules of the invention may be prepared in GVB at a concentration of 0.8μM for dilution. (This concentration may be adjusted up or down, depending on the activity of the particular molecule). Standards using MCP or MCP-DAF may be formulated using 80 μM MCP or 0.8 μM MCP-DAF. Four serial 1:2 dilutions of the standard solution are prepared. The assays are then conducted by adding the foUowing components to dupHcate weUs of a V-bottom microtiter plate: Experimentals 100 μl SRBC suspension; 50 μl standard solution or dilution; 50 μl of serum dilution Negative control 100 μl SRBC suspension; 50 μl standard solution; 50 μl GVB Positive control 100 μl SRBC suspension which has been spun down as above and resuspended in 200 μl of water The plate is incubated at 37 degrees C for 30 minutes. The plates are then subjected to centrifugation at 500 x g for 1 minute (2 to 8 degrees C) and 100 μl of the resulting supernatant Hquid is drawn off. The absorbance of each sample is then measured at 405 nm. Percent positive control SRBC lysis for each dilution is then calculated according to the formula: {[O.D.sample-O.D.neg.control]/ [O.D.pos.control-O.D.neg.control]} x 100. The % inhibition is 100% -(% positive control). Factor I Assay Standards are prepared by dilution of the molecules of the invention into 20μl of Assay Buffer (3 mM sodium phosphate, pH 7.2; 25 mM sodium chloride; 0.5% NP-40) to a concentration of approximately 6.0 nM. Five serial 1:2 dilutions are then prepared. For each assay 6 ul of the serial -dilutions are added to 2 μl of Factor I solution and 8 μl of iC3 solution. Factor I Stock Solution is prepared using 1 mg Factor I (Quide catalog #A411) in 1 ml Assay Buffer. Immediately before use, 4 ul of Factor I Stock Solution is added to 50 μl Assay Buffer to prepare the Factor I solution. iC3 solution is prepared using 0.5 mg purified C3 (Quidel, catalog #A401) in 1 ml Assay Buffer. An equal amount of 4.0M potassium bromide is added and the iC3.Solution is incubated at 37 degrees C for 1 hour, protecting the mixture from light Negative controls are also prepared using: 8 μl iC3 solution, 6 μl Assay Buffer and 2 μl Factor I solution. The samples are then incubated for 1 hour at 37 degrees G The reactions are stopped by addition of SDS Sample Buffer (20% sucrose; 2 % sodium dodecyl sulfate; 100 mM Tris, pH 6.8; 20 mM dithiothreitol; 0.01 % bromphenol blue) to each tube. The samples are then boiled in a 100 degree water bath for five minutes and allowed to cool to room temperature. The samples are then subjected to electrophoresis on a 10% polyacrylamide gel. The gel is stained for 1 hour in 50% methanol; 10% acetic acid; 0.05% Coomassie BrilHant Blue. The gel may then be destained overnight in 15% methanol and 10% acetic acid. The gel is dried and the lanes of the gel may be scanned using a densitometer. The C3α chain has a native molecular weight of 120kD and is cleaved into 75kD and 45kD fragments. The area under the three peaks corresponding to each complement component is determined and the percentage of the total area each peak represents is calculated. The percentage cleavage of the alpha chain is calculated as foUows: % cleavage = 100% - (% of total area which is native mw). Deposit Information The foUowing materials were deposited with the American Type Culture CoUection: Plasmid Deposit Date Accession No. ρAcC13preproPR-3 January 27, 1994 69542 The above materials were deposited by Chiron Corporation, an assignee of the present invention with the American Type Culture CoUection (ATCQ, 12301 Parklawn Drive, RockviUe, Maryland under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for purposes of Patent Procedure. The accession number is avaUable from the ATCC at telephone number (301) 881-2600. These deposits are provided as convenience to those of skiU in tire art, and are not an admission that a deposit is required under 35 U.S.G §112 The nucleic acid .sequence of any of the.se deposits, as weU as the amino acid .sequence of the polypeptides encoded thereby, are incorporated herein by reference and should be referred to in the event of an error in the sequence described herein, A Hcense may be required to make, use, or seU the deposited materials, and no such Hcense is granted hereby. SEOUENCE LISTING C ys G luGluProProThrPheGluAleiMetGluLeuIleGlyLysProLysProTyrTyrGluIleGlyGl uArgValAspTyrLysCysLysLysGlyTyrPheTyrlleProProLeuAlaThrHisThrlleCysAspA rgAsnHisThrTrpLeuProValSerAspAspAlaCysTyrArgGluThrCysProTyrlleArgAspPro LeuAsnGlyGlnAlaValProAlaAsnGlyThrTyrGluPheGlyTyrGlnMetHisPhelleCysAsnGl uGly T yrTyrLeuIleGlyGluGluIleLeuTyrCyβGluLeuLysGlySerValAlalleTrpSerGlyL ys P roProIleCysGluLysValLeuCysThrProProProLysIle ysAsnGlyLysHisThrPheSer GluValGluValPheGluTyrLβuAspAlaValThrTyrSerCysAspProAlaProGlyProAspProPh eSerLeuIleGlyGluSerThrlleTyrCysGlyAspAsnSerValTrpSerArgAlaAlaProGluCysL ysValValLysCysArgPheProValValGluAsnGlyLysGlnlleSerGlyPheGlyLysLysPheTyr TyrLysAlaThrValMetP eGluCysAspLysGlyPheTyrLeuAspGlySerAspThrlleValCysAs pSerAsnSerThrTrpAspProProValProLysCysLeuLysValSerThr (SEQ ID NO: 1) AspCysGlyLeuProProAspValProAsnAlaGlnProAlaLeuGluGlyArgThrSerPheProGluAs pThrVallleThrTyrLysCysGluGluSerPheValLysIleProGlyGluLysAspSerVallleCysL euLysGlySerGlnTrpSerAspIleGluGluPheCysAsnArgSerCysGluValProThrArgLeuAsn SerAlaSerLeuLysGlnProTyrlleThrGlnAsnTyrPheProValGlyThrValValGluTyrGluCy sArgProGlyTyrArgArgGluProSerLeuSerProLysLeuThrCysLeuGlnAsnLeuLysTrpSerT hrAlaValGluPheCysLysLysLysSerCysProAsnProGlyGluIleArgAsnGlyGlnlleAspVal ProGlyGlylleLeuPheGlyAlaThrlleSerPheSerCysAsnThrGlyTyrLysLeuPheGlySerTh rSerSerPheCysLeuIleSerGlySerSerValGlnTrpSerAspProLeuProGluCysArgGluIleT yrCysProAlaProProGlnlleAspAsnGlyllelleGlnGlyGluArgAspHisTyrGlyTyrArgGln SerValThrTyrAlaCysAsnLysGlyPheThrMetlleGlyGluHisSerlleTyrCysThrValAsnAs nAspGluGlyGluTrpSerGlyProProProGluCysArgGlyLysSerLeuThrSerLyβValProProT hrValGlnLysProThrThrValAsnValProThrThrGluValSerProThrSerGlnLysThrT rT r LysThrThrThrProAsnAlaGlnAlaThrArgSerThrProValSerArgThrThrLysHisPheHisGl uThrThrProAsnLysGlySerGlyThrThrSerGlyThrThrArg (SEQ ID NO: 2) CysGluGluProProThrPheGluAlaMetGluLeuIleGlyLysProLysProTyrTyrGluIleGlyGl uArgValAspTyrLysCysLysLysGlyTyrPheTyrlleProProLeuAlaThrHisThrlleCysAspA rgAsnHisThrTrpLeuProValSerAspAspAlaCysTyrArgGluThrCysProTyrlleArgAspPro LeuAsnGlyGlnAlaValProAlaAsnGlyThrTyrGluPheGlyTyrGlnMetHisPhelleCysAsnGl uGlyTyrTyr euIleGlyGluGluIleLeuTyrCysGluLeuLysGlySerValAlalleTrpSerGly ysProProIleCysGluLysValLeuCysThrProProProLysIleLysAsnGlyLysHisThrPheSer GluValGluValPheGluTyrLeuAspAlaValThrTyrSerCysAspProAlaProGlyProAspProPh eSerLeuIleGlyGluSerThrlleTyrCysGlyAspAsnSerValTrpSerArgAlaAlaProGluCysL ysValValLysCysArgPheProValValGluAsnGlyLysGlnlleSerGlyPheGlyLysLysPheTyr TyrLysAlaThrValMetPheGluCysAspLysGlyPheTyrLeuAspGlySerAspThrllβValCyβAβ pSerAsnSerThrTrpAspProProValProLysCysLeuLysValSerThrAspCysGlyLeuProProA spValProAsnAlaGlnProAlcΛeuGluGlyArgThrSerPheProGluAspThrVallleThrTyrLyβ CysGluGluSerPheValLysIleProGlyGluLysAspSerVallleCysLeuLysGlySerGlnTrpSe rAspIleGluGluPheCysAsnArgSerCysGluValProThrArg euAsnSerAlaSerLeuLysGlnP roTyrIleThrGlnAsnTyrPheProValGlyThrValValGluTyrGluCysArgProGlyTyrArgArg GluProSerLeuSerProLysLeuThrCysLeuGlnAsnLeuLysTrpSerThrAlaValGluPheCysLy sLysLysSerCysProAsnProGlyGluIleArgAsnGlyGlnlleAspValProGlyGlylleLeuPheG lyAlaThrlleSerPheSerCysAβnThrGlyTyrLys euPheGlySerThrSerSerPheCys euIle SerGlySerSerValGlnTrpSerAspProLeuProGluCysArgGluIleTyrCysProAlaProProGl nlleAspAsnGlyllelleGlnGlyGluArgAspHisTyrGlyTyrArgGlnSerValThrTyrAlaCyβA sn ysGlyPheThrMetlleGlyGluHisSerlleTyrCysThrValAsnAsnAspGluGlyGluTrpSer GlyProProProGluCysArgGlyLysSerLeuThrSerLysValProProThrValGlnLysProThrTh rValAsnValProThrThrGluValSerProThrSerGlnLysThrThrThrLysThrThrThrProAsnA laGlnAlaT rArgSerThrProValSerArgThrThrLysHisPheHisGluThrThrProAsnLysGly SerGlyT rThrSerGlyThrThrArg (SEQ ID NO: 3) Ala-Lyβ-Arg-Gly-Leu-Arg-Arg-Arg-Leu-Gly-Arg-Lys-Ala (SEQ ID NO: 4) Ala-Arg-Arg-Gly-Lys-Leu (SEQ ID NO: 5) Trp-Gln-Pro-Pro-Arg-Ala-Arg-Ile (SEQ ID NO: 6) Leu-Ile-Gly-Arg-Lys-Lys (SEQ ID NO: 7) Ala Lys Leu Asn Cys Arg Leu Tyr Arg Lys Ala Asn Lys Ser Ser Lys Leu (SEQ ID NO: 8) Thr Ser Asp Gin lie His Phe Phe Phe Ala Lys Leu Asn Cys Arg. (SEQ ID NO: 9) Ser Glu Lys Thr Leu Arg Lys Trp Leu Lys Met Phe Lys Lys Arg Glu Leu Glu Glu Tyr (SEQ ID NO: 10) His Arg His His Pro Arg Glu Met Lys Lys Arg Val Glu Asp Leu (SEQ ID NO: 11) Phe Arg Lys Leu Thr His Arg Leu Phe Arg Arg Asn Phe Gly Tyr Thr Leu Arg (SEQ ID NO: 12) Leu Tyr Lys Lys lie Leu Lys Lys Leu Leu Glu Ala (SEQ ID NO: 13) Asn Gly Leu Lys Arg Asp Lys Leu Gly Cys Glu Tyr Cys Glu Cys Arg Pro Lys Arg Lys Leu lie Pro Arg Leu Ser (SEQ ID NO: 14) Lys Thr Lys Arg Lys Arg Lys Lys Gin Arg Val Lys lie Ala Tyr Glu Glu lie Phe Val Lys Asn Met (SEQ ID NO: 15) Lys Lys Lys Lys Lys Met Pro Lys Leu Arg Phe Ala Ser Arg lie Arg Lys lie Arg Lys Lys Gin Phe (SEQ ID NO: 16) CTGCTTTCCTCCGGAGAAATAACAGCGTCTTCCGCGCCGCGCATGGAGCCTCCCGGCCGCCGCGAGTGTCC CTTTCCTTCCTGGCGCTTTCCTGGGTTGCTTCTGGCGGCCATGGTGTTGCTGCTGTACTCCTTCTCCGATG CCTGTGAGGAGCCACCAACATTTGAAGCTATGGAGCTCATTGGTAAACCAAAACCCTACTATGAGATTGGT GAACGAGTAGATTATAAGTGTAAAAAAGGATACTTCTATATACCTCCTCTTGCCACCCATACTATTTGTGA TCGGAATCATACATGGCTACCTGTCTCAGATGACGCCTGTTATAGAGAAACATGTCCATATATACGGGATC CTTTAAATGGCCAAGCAGTCCCTGCAAATGGGACTTACGAGTTTGGTTATCAGATGCACTTTATTTGTAAT GAGGGTTATTACTTAATTGGTGAAGAAATTCTATATTGTGAACTTAAAGGATCAGTAGCAATTTGGAGCGG TAAGCCCCCΛATATGTGAAAAGGTTTTGTGTACACCΛCCTCCΛAAAATAAAAAATGGAAAACACACCTTTA GTGAAGTAGAAGTATTTGAGTATCTTGATGCAGTAACTTATAGTTGTGATCCTGCACCTGGACCAGATCCA TTTTCACTTATTGGAGAGAGCACGATTTATTGTGGTGACAATTCAGTGTGGAGTCGTGCTGCTCCAGAGTG TAAAGTGGTCAAATGTCGATTTCCAGTAGTCGAAAATGGAAAACAGATATCAGGATTTGGAAAAAAATTTT ACTACAAAGCAACAGTTATGTTTGAATGCGATAAGGGTTTTTACCTCGATGGCAGCGACACAATTGTCTGT GACAGTAACAGTACTTGGGATCCCCCAGTTCCAAAGTGTCTTAAAGTGTCGACTGACTGTGGCCTTCCCCC AGATGTACCTAATGCCCAGCCAGCTTTGGAAGGCCGTACAAGTTTTCCCGAGGATACTGTAATAACGTACA AATGTGAAGAAAGCTTTGTGAAAATTCCTGGCGAGAAGGACTCAGTGATCTGCCTTAAGGGCAGTCAATGG TCAGATATTGAAGAGTTCTGCAATCGTAGCTGCGAGGTGCCAACAAGGCTAAATTCTGCATCCCTCAAACA GCCTTATATCACTCAGAATTATTTTCCAGTCGGTACTGTTGTGGAATATGAGTGCCGTCCAGGTTACAGAA GAGAACCTTCTCTATCACCAAAACTAACTTGCCTTCAGAATTTAAAATGGTCCACAGCAGTCGAATTTTGT AAAAAGAAATCATGCCCTAATCCGGGAGAAATACGAAATGGTCAGATTGATGTACCAGGTGGCATATTATT TGGTGCAACCATCTCCTTCTCATGTAACACAGGGTACAAATTATTTGGCTCGACTTCTAGTTTTTGTCTTA TTTCAGGCAGCTCTGTCCAGTGGAGTGACCCGTTGCCAGAGTGCAGAGAAATTTATTGTCCAGCACCACCA CAAATTGACAATGGAATAATTCAAGGGGAACGTGACCATTATGGATATAGACAGTCTGTAACGTATGCATG TAATAAAGGATTCACCATGATTGGAGAGCACTCTATTTATTGTACTGTGAATAATGATGAAGGAGAGTGGA GTGGCCCACCACCTGAATGCAGAGGAAAATCTCTAACTTCCAAGGTCCCACCAACAGTTCAGAAACCTACC ACAGTAAATGTTCCAACTACAGAAGTCTCACCAACTTCTCAGAAAACCACCACAAAAACCACCACACCAAA TGCTCAAGCAACACGGAGTACACCTGTTTCCAGGACAACCAAGCATTTTCATGAAACAACCCCAAATAAAG GAAGTGGAACCACTTCAGGTACTACCCGTTGA (SEQ ID NO: 17) CAGAGAATTCTCAAGCTTTTCTACCTAGTCTTCTTCTTAGACCTCTTTTAGCTCGGGTAGTACCTGAAGTG GT (SEQ ID NO: 18). CAGAGGTACCATGGAGCCTCCCGGCCGCCGC (SEQ ID NO: 19). CAGAGAATTCTCATAGTTTACCTCTTCTAGCTCGGGTAGTACCTGAAGTGGT (SEQ ID NO: 20). CAGAGAATTCTCACATATTTTTAACAAAAATTTCTTCATATGCTATTTTCACTCTCTGCTTCTTTCTTTTT CTTTTGGTTTTTCGGGTAGTACCTGAAGTGGT (SEQ ID NO: 21). ACTTCAGGTACTACCCGTAAAACCAAAAGA (SEQ ID NO: 22) TGAAGTCCATGATGGGCATTTTGGTTTTCTTTTTCT (SEQ ID NO: 23). CAGAGAATTCTCACATATTTTTAACAAAAATTTC (SEQ ID NO: 24). CAGAGAATTCTCATATTCTAGCTCTAGGAGGCTGCCATCGGGTAGTACCTGAAGTGGT (SEQ ID NO: 25). CAGAGAATTCTCAGGTTTTTTTTCTACCTATTAGTCGGGTAGTACCTGAAGTGGT (SEQ ID NO: 26).

Claims: We Qaim: 1. A chimeric protein, comprising a protein represented by the foUowing formula: wherein A and C are peptide sequences 0-25 amino acids in length and capable of binding to glycosaminoglycans; wherein Ri comprises MCP or DAF; wherein the R2 component is DAF when Ri is MCP and is MCP when wherein B is a peptide of any length, including zero, and may or may not have biological activity including complement inhibiting a-ctivity. 2. The chimeric protein of claim 1, wherein RI comprises MCP and R2 comprises DAF. 3. The chimeric protein of claim 2, wherein B is 0 amino acids in length. 4. The chimeric protein of claim 3, wherein A is 0 amino acids in length. 5. The chimeric protein of claim 4, wherein C is a peptide represented by the formula: XBBXXBBBXXBBX where X represents hydropathic amino acids and B represents the basic amino acids lysine and arginine. 6. The chimeric protein of claim 5, wherein C is SEQ ID NO: 4. 7. The chimeric protein of claim 4, wherein C is a peptide represented by the formula: XBBXBX where X represents hydropathic amino acids and B represents the basic amino acids lysine and arginine. 8. The chimeric protein of claim 7, wherein C is SEQ ID NO: 5. 9. The chimeric protein of claim 4, wherein C is SEQ ID NO: 6. 10. The chimeric protein of claim 4, wherein C is SEQ ID NO: 7. 11. The chimeric protein of claim 4, wherein C is SEQ ID NO: 15. 12. A nucleotide sequence comprising, a nucleotide sequence capable of encoding a chimeric protein, said chimeric protein being represented by the foUowing formula: wherein A and C are peptide sequences 0-25 amino acids in length and capable of binding to glycosaminoglycans; wherein Ri comprises MCP or DAF; wherein the R∑ component is DAF when Ri is MCP and is MCP when wherein B is a peptide of any length, including zero, and may or may not have biological activity including complement inhibiting activity. 13. A transformed host ceU, said tranf ormed host ceU comprising a nucleotide sequence capable of encoding a chimeric protein, said chimeric protein being represented by the foUowing formula: wherein A and C are peptide sequences 0-25 amino acids in length and capable of binding to glycosaminoglycans; wherein Ri comprises MCP or DAF; wherein the R2 component is DAF when Ri is MCP and is MCP when wherein B is a peptide of any length, including zero, and may or may not have biological activity including complement inhibiting activity and said nucleotide sequence being capable of being expressed within said hostceU.

Inventors: CREASEY ABLA A, INNIS MICHAEL A, ZAROR ISABEL, CREASEY, ABLA, A., INNIS, MICHAEL, A., ZAROR, ISABEL
Applicants: CHIRON CORP, CHIRON CORPORATION
Application year: 1996
Main classification: C12N15
IPC codes: A61K38, C07K14, C07K19, C12N15